VistaGen Therapeutics, Inc. — FY2018 Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2018; filed June 26, 2018. Although the request identifies 2017 Q4, this filing is an annual report for FY2018, with comparative FY2017 results and unaudited quarterly data.
Business context
VistaGen is a clinical-stage biopharmaceutical company with no approved products or product-sale revenue. Its lead candidate, oral AV-101, was in Phase 2 development for major depressive disorder (MDD). The company also operates VistaStem, a stem-cell technology and drug-rescue program, and licensed certain cardiac stem-cell technology to BlueRock Therapeutics.
Financial results and liquidity
| Metric | FY2018 | FY2017 |
|---|---|---|
| Revenue | $0 | $1.25 million |
| Research and development expense | $7.76 million | $5.20 million |
| General and administrative expense | $6.44 million | $6.29 million |
| Net loss | $14.35 million | $10.26 million |
| Net loss attributable to common stockholders | $15.58 million | $11.62 million |
| Loss per common share | $1.12 | $1.54 |
| Cash used in operating activities | $9.06 million | $7.26 million |
Operating margins are not meaningful because FY2018 revenue was zero. The FY2017 sublicense revenue was a one-time $1.25 million BlueRock upfront payment; the company reported no recurring revenue-generating arrangements.
- At March 31, 2018, cash and cash equivalents were $10.38 million, versus $2.92 million a year earlier. Current assets were $11.02 million and current liabilities $1.46 million.
- Total liabilities were $4.36 million, including $2.61 million of accrued Series B preferred dividends. Interest-bearing notes payable were $53,900; capital-lease obligations totaled $11,900.
- Stockholders’ equity was $6.92 million; accumulated deficit was $156.54 million. The company had 23.07 million common shares outstanding at year-end and 23.04 million as of June 26, 2018.
- Financing activities provided $16.52 million in FY2018, principally from equity and warrant offerings. December 2017’s public offering generated $15.0 million gross and about $13.6 million net proceeds.
Changes versus prior year and notable items
- Net loss increased about 40%, while R&D expense rose about 49%, primarily due to AV-101 development and preparation for the ELEVATE study. R&D spending is expected to increase significantly in FY2019.
- Operating cash use increased by about $1.80 million. Cash at year-end increased largely because of equity financing, not operating cash generation.
- FY2018 included a $135,000 loss on settling $526,500 of CMO accounts payable using $585,000 in common stock fair value and a $76,500 cash payment.
- Preferred-stock charges included $1.03 million of accrued Series B dividends and a $199,200 deemed dividend when a down-round warrant provision was triggered. These reduced earnings attributable to common holders but were not operating cash expenses.
- Common shares issued and outstanding rose from 8.97 million at March 31, 2017 to 23.07 million at March 31, 2018. The filing also reports 16.60 million outstanding warrants and 5.30 million options at year-end, representing substantial potential dilution.
Outlook, risks, and controls
- VistaGen initiated the Phase 2 ELEVATE study in early 2018 and anticipated top-line results in the first half of 2019. The NIMH was conducting and funding a separate Phase 2 AV-101 monotherapy study; the filing anticipated its completion during 2018.
- Management said AV-101 would require additional studies, including at least two Phase 3 trials for the initial MDD adjunctive indication; the company stated approval was unlikely before at least 2021. These are forward-looking expectations, not assurances.
- Management estimated approximately $13 million of cash expenditures for the 12 months after issuance of the financial statements, exceeding March 31 cash. Management and the auditor reported substantial doubt about the company’s ability to continue as a going concern without additional financing. Funding plans included equity issuance, collaborations, and grants; availability and terms were uncertain.
- Key risks include clinical-trial efficacy and safety, regulatory approval, dependence on AV-101, financing and dilution, reliance on outside manufacturers and research organizations, reimbursement, competition, and intellectual-property protection. Most future programs remained preclinical or exploratory.
- The auditor issued an unqualified opinion on the financial statements but included a going-concern emphasis. Management reported ineffective internal control over financial reporting due to inadequate segregation of duties and accounting software limitations; disclosure controls were described as effective.
- No legal proceedings were reported. The filing identifies no off-balance-sheet financing arrangements beyond normal-course contractual obligations.
Most important facts for investors to verify
- Whether ELEVATE and the NIMH study produced results consistent with the company’s stated timeline and development expectations.
- Cash burn, financing raised after March 31, 2018, and the resulting runway and dilution; the filing’s $13 million 12-month expenditure estimate exceeded year-end cash.
- Current common shares outstanding, preferred-stock conversion and dividend terms, and potential dilution from warrants and options.
- Whether material weaknesses in financial controls were remediated and whether subsequent filings report control or reporting issues.
- Whether BlueRock milestones, royalties, or new collaborations generated revenue; FY2018 had no revenue and the BlueRock payment was received in FY2017.